Zhixiang Jintai (688443.SH) signed a commercial cooperation agreement for the sale of Wecadocta monoclonal antibody injection and Sleciubem monoclonal antibody injection.

Zhitan Finance News App, Zhixiang Jintai (688443.SH) announced that recently, the company signed exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings Limited (referred to as "Kangzhe Pharmaceutical") affiliated company Tibet Kangzhe Pharmaceutical Development Co., Ltd. (referred to as "Tibet Kangzhe") and RXILIENT MEDICAL PTE. LTD. (referred to as "RXILIENT") respectively for the exclusive commercialization rights in mainland China of the monoclonal antibody injections Wei Kang Duta (GR2001 injection) and Sleweimi (GR1801 injection). According to the agreements, the company will receive initial payments, milestone payments, and commercialization support services, Tibet Kangzhe will gain exclusive commercialization rights of the two products in mainland China, and RXILIENT will obtain exclusive licensing rights for the two products in the Asia-Pacific region, Middle East, and North Africa excluding mainland China.